Market Research Logo

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2018

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2018

Summary

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target cons


Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AB Science SA
Almirall SA
Archer Pharmaceuticals Inc
Asana BioSciences LLC
Beijing Hanmi Pharmaceutical Co Ltd
Celgene Corp
Clevexel Pharma SAS
Fujifilm Holdings Corporation
Genosco Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
Japan Tobacco Inc
Levolta Pharmaceuticals Inc
Millennium Pharmaceuticals Inc
Portola Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd
TopiVert Ltd
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles
AB-8779 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-509 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entospletinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FF-10102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-492429 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2646264 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAS-189386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilvadipine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKIO-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-659 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-05567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting
Oct 18, 2018: Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
Oct 11, 2018: Rigel receives EMA validation of the marketing authorization application for Fostamatinib Disodium Hexahydrate in chronic immune thrombocytopenia (ITP) in adult patients
Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma
Sep 10, 2018: Asana BioSciences to present late-breaking clinical and biomarker data for its JAK/SYK inhibitor ASN002 at the European Academy of Dermatology and Venereology Annual Congress
Jul 20, 2018: Asana starts Phase llb trial of ASN002 for atopic dermatitis
Jun 20, 2018: Rigel Announces Poster Presentations at FOCIS Annual Meeting
Jun 18, 2018: US Bioservices selected by Rigel Pharmaceuticals to dispense TAVALISSE (fostamatinib disodium hexahydrate) Tablets
Jun 12, 2018: Rigel to present phase 2 results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib
May 30, 2018: Rigel Appoints Dean Schorno as Chief Financial Officer
May 29, 2018: Rigel Announces Availability of TAVALISSE (fostamatinib disodium hexahydrate) in the U.S.
May 29, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Approved by FDA, Available for Order at Biologics
Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AB Science SA, H2 2018
Pipeline by Almirall SA, H2 2018
Pipeline by Archer Pharmaceuticals Inc, H2 2018
Pipeline by Asana BioSciences LLC, H2 2018
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Clevexel Pharma SAS, H2 2018
Pipeline by Fujifilm Holdings Corporation, H2 2018
Pipeline by Genosco Inc, H2 2018
Pipeline by Gilead Sciences Inc, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Hutchison MediPharma Ltd, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by Levolta Pharmaceuticals Inc, H2 2018
Pipeline by Millennium Pharmaceuticals Inc, H2 2018
Pipeline by Portola Pharmaceuticals Inc, H2 2018
Pipeline by Rigel Pharmaceuticals Inc, H2 2018
Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018
Pipeline by TopiVert Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Dormant Products, H2 2018 (Contd..3), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report